WoodTrust Financial Corp Sells 1,750 Shares of DexCom, Inc. (NASDAQ:DXCM)

WoodTrust Financial Corp decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 13.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,810 shares of the medical device company’s stock after selling 1,750 shares during the quarter. WoodTrust Financial Corp’s holdings in DexCom were worth $724,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the 2nd quarter worth $25,000. Sachetta LLC grew its holdings in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the last quarter. Crewe Advisors LLC bought a new position in DexCom in the 1st quarter worth approximately $29,000. Riverview Trust Co lifted its holdings in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, DT Investment Partners LLC boosted its position in shares of DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ:DXCM opened at $68.61 on Thursday. The stock has a market capitalization of $26.80 billion, a P/E ratio of 41.08, a price-to-earnings-growth ratio of 2.14 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm has a 50 day moving average of $69.66 and a 200-day moving average of $94.30.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on DXCM shares. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Morgan Stanley dropped their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Wells Fargo & Company lifted their target price on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Leerink Partners cut their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.